Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 10.62B +77.2% |
| Revenue (ttm) | 1.06B +47.5% |
| Net Income | -326.98M |
| EPS | -2.02 |
| Shares Out | 165.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,423,390 |
| Open | 67.78 |
| Previous Close | 84.46 |
| Day's Range | 64.10 - 70.35 |
| 52-Week Range | 40.03 - 86.74 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 100.82 (+56.87%) |
| Earnings Date | Jul 29, 2026 |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for IONS stock is "Buy." The 12-month stock price target is $100.82, which is an increase of 56.87% from the latest price.
News
Ionis Pharmaceuticals price target lowered to $90 from $113 at Jefferies
Jefferies analyst Akash Tewari lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $90 from $113 and keeps a Buy rating on the shares after the CARDIO-TTRansform Phase 3…
Ionis Pharmaceuticals price target lowered to $86 from $105 at Needham
Needham analyst Joseph Stringer lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $86 from $105 and keeps a Buy rating on the shares after the company and partner…
Ionis Pharmaceuticals falls -22.5%
Ionis Pharmaceuticals (IONS) is down -22.5%, or -$18.99 to $65.47.
Ionis Pharmaceuticals price target lowered to $94 from $108 at TD Cowen
TD Cowen lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $94 from $108 and keeps a Buy rating on the shares after the company and AstraZeneca’s (AZN) CARDIO-TTRansform…
Ionis Pharmaceuticals price target lowered to $87 from $104 at Raymond James
Raymond James lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $87 from $104 and keeps an Outperform rating on the shares. The disappointing CARDIO-TTRansform trial results significa...
Ionis Pharmaceuticals price target lowered to $90 from $111 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $90 from $111 and keeps a Buy rating on the shares. Given supportive precedent in the…
Alnylam price target raised to $468 from $420 at Raymond James
Raymond James raised the firm’s price target on Alnylam (ALNY) to $468 from $420 and keeps an Outperform rating on the shares. Ionis’ (IONS) failed Phase 3 ATTR-CM trial strengthens…
Ionis Pharmaceuticals (IONS) Stock Slammed by Phase 3 Trial Results
Ionis Pharmaceuticals stock fell hard on Thursday due to a clinical trial failure.
Ionis Pharmaceuticals falls -17.6%
Ionis Pharmaceuticals (IONS) is down -17.6%, or -$14.84 to $69.62.
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
Ionis, AstraZeneca report CARDIO-TTRansform trial misses primary endpoint
Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not mee...
AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint
The CARDIO-TTRansform Phase III trial for AstraZeneca (AZN) and Ionis’ (IONS) Wainua in patients with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint of the co...
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis , failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-...
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthy...
Ionis completes enrollment in Cohort 1 of Phase 3 REVEAL study
Ionis Pharmaceuticals (IONS) has completed enrollment in the pivotal cohort of the global Phase 3 REVEAL study evaluating obudanersen, an investigational RNA-targeted medicine for people living with A...
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evalu...
Ionis Pharmaceuticals price target raised to $130 from $125 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $130 from $125 and keeps a Buy rating on the shares following the FDA approval of Tryngolza. Published…
Ionis Pharmaceuticals enters zilganersen license agreement with Recordati
Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement with Recordati, under which Recordati obtained exclusive rights to develop and commercialize zilganersen, an investi...
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Recordati (“Recordati”), under which Recordati obtained ...
Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $75 from $74 and keeps a Neutral rating on the shares. The firm cites the FDA having approved…
Ionis Pharmaceuticals Transcript: FDA announcement
TRYNGOLZA received FDA approval as the first therapy to reduce triglycerides and acute pancreatitis risk in adults with sHTG, supported by robust phase III data showing up to 72% triglyceride reduction and 91% reduction in pancreatitis events. The launch will focus on high-risk patients, with broad payer access and strong support programs expected to drive adoption.
Ionis Pharmaceuticals Slides: FDA announcement
Ionis Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.
Ionis Pharmaceuticals Press release: FDA announcement
Ionis Pharmaceuticals issued a press release on June 24, 2026, disclosing material business information to investors.
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA® (olezarsen) as an adjunct to diet...